Dermatologicals
Refine search
Pharmaceutical
Spanish dermatology specialist Almirall today inaugurated new offices in Jing’an, Shanghai, establishing a presence dedicated to life science innovation and business development in medical dermatology in China, complementary to its in-house R&D in Barcelona. 12 March 2026
Biotechnology
Belgium’s largest drugmaker UCB has announced positive topline data from the BE BOLD trial assessing Bimzelx bimekizumab) versus Skyrizi (risankizumab) in adults living with active psoriatic arthritis (PsA). 11 March 2026
Pharmaceutical
Medicus Pharma has announced top-line results from its Phase II study of doxorubicin microneedle array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. 5 March 2026
Pharmaceutical
Priovant Therapeutics today announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for brepocitinib for the treatment of dermatomyositis (DM) and has granted the application Priority Review. 3 March 2026
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended 6 novel medicines for approval at its February 2026 meeting. These now have to be approved by the European Commission, which usually takes two months or so. 27 February 2026
Biotechnology
Swiss dermatology focused biopharma Galderma today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio (nemolizumab) in moderate-to-severe prurigo nodularis. 27 February 2026
Biotechnology
US biopharma company Incyte’s UK subsidiary today announces that the National Institute for Health and Care Excellence (NICE) has approved the reimbursement of Opzelura (ruxolitinib) cream 15mg/g for eligible patients with non-segmental vitiligo on the National Health Service (NHI). 24 February 2026
Pharmaceutical
Spanish dermatology-focused pharma Almirall reported full-year 2025 net sales of 1.1 billion euros ($1.2 billion), up 12%, as total revenue rose 13% to 1.1 billion euros. EBITDA increased 21% to 233 million euros, while net income climbed to 46 million euros from 10 million euros a year earlier. 23 February 2026
Biotechnology
US drugmaker Eli Lilly has announced positive top-line results from the landmark TOGETHER-PsO open-label Phase IIIb trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related comorbid condition. 19 February 2026
Pharmaceutical
US pharma giant Merck & Co and hospital system Mayo Clinic have announced a research and development agreement to apply artificial intelligence (AI), advanced analytics and multimodal clinical data, to support drug discovery and development. 19 February 2026
Pharmaceutical
Swiss pharma giant Novartis has announced positive topline results from its pivotal Phase III RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU). 18 February 2026
Biotechnology
US clinical-stage biotech Evommune has entered into a securities purchase agreement to sell 4,494,279 shares of its common stock to a select group of new and existing mutual funds and dedicated healthcare institutional investors in a private placement. 16 February 2026
Pharmaceutical
US dermatology specialist Verrica Pharmaceuticals has announced the appointment of Chris Chapman as its chief commercial officer (CCO). 13 February 2026
Pharmaceutical
US dermatologics specialist Verrica Pharmaceuticals) today announced the launch of Ycanth in Japan by its partner, Torii Pharmaceutical, a wholly-owned subsidiary of Japan’s Shionogi, for the treatment of molluscum contagiosum (molluscum). 9 February 2026
Biotechnology
The Roivant Sciences subsidiary Priovant Therapeutics has announced positive results from the Phase II BEACON study of brepocitinib in cutaneous sarcoidosis (CS). 9 February 2026
Biotechnology
USA-based clinical-stage dermatology start-up Veradermics has announced the pricing of its upsized initial public offering of 15,077,647 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Veradermics. 5 February 2026
Biosimilars
Russian drugmaker Binnopharm Group together with China’s Mabwell announced plans to localize the production of a monoclonal antibody (MAb)-based drug for the treatment of asthma and atopic dermatitis in Russia. 4 February 2026
Biotechnology
Belgium’s largest drugmaker UCB today announced three-year data from the BE HEARD trials^ for Bimzelx (bimekizumab) in moderate to severe HS. 4 February 2026
Biotechnology
US clinical-stage biotech Sagimet Biosciences’ shares rose 10% to $6.23 after it announced that China-based partner Ascletis Pharma reported positive top-line results in the open-label Phase III trial evaluating the long-term safety of ASC-40 (denifanstat) tablets in patients with moderate to severe acne. 3 February 2026
Biotechnology
The US Food and Drug Administration (FDA) last week lifted the clinical hold on Intellia Therapeutics’ investigational new drug (IND) for its nexiguran ziclumeran (nex-z) for amyloidosis. The US Centers for Medicare and Medicaid Services (CMS) has released the names of 15 more drugs for a third cycle of Medicare price negotiations. On the deal-making front, Moderna signed a commercialization collaboration with Italy’s Recordati on mRNA-3927, and Japan’s Kyowa Kirin revealed that its partner Amgen has terminated the collaboration on dermatology candidate rocatinlimab. 1 February 2026
Biotechnology
US healthcare giant Johnson & Johnson has acquired Yellow Jersey Therapeutics (YJT), a wholly-owned subsidiary of Swiss biotech Numab Therapeutics. 29 May 2024
Biotechnology
Johnson & Johnson has entered into a definitive agreement to acquire Proteologix, the US healthcare giant revealed yesterday. 17 May 2024
Pharmaceutical
Dermatology company Verrica Pharmaceuticals has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical. 16 May 2024
Pharmaceutical
Spanish dermatology company Almirall impressed investors with its financial results for the first quarter of 2024, which were presented on Monday. 13 May 2024
Pharmaceutical
Swiss drug developer Atopia Therapeutics has appointed Dr Grégoire Chevalier as chief executive (CEO). 7 May 2024
Biotechnology
Pennsylvania, USA-based clinical-stage biotech SFA Therapeutics has appointed of Dr Stefan Weiss as chief medical officer. 3 May 2024
Biotechnology
Shares of USA-based Regeneron dipped 1.8% after reporting first-quarter 2024 financial results that fell short of Wall Street expectations. 2 May 2024
Biosimilars
The US Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm). 1 May 2024
Biotechnology
US pharma major AbbVie on Thursday announced positive top-line results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase IIIb/IV study that evaluated the efficacy and safety of Rinvoq (upadacitinib). 26 April 2024
Pharmaceutical
Belgium’s largest drugmaker UCB today announced an update on its progress at its annual shareholder meeting (AGM), with the news edging its shares up 1.7% to 122.90 by midday. 25 April 2024
Biotechnology
US biopharma Abeona Therapeutics was trading nearly 50% lower in Tuesday morning’s trading after announcing a regulatory update for prademagene zamikeracel (pz-cel). 23 April 2024
Pharmaceutical
Swiss pharma giant Novartis today raised its full-year guidance after reporting better-than-expected first-quarter 2024 results, with the firm’s shares rising as much as 4.8% in early trading. 23 April 2024
Biotechnology
The European Commission (EC) has granted marketing authorization for the interleukin (IL)-17A and IL-17F inhibitor Bimzelx (bimekizumab), from Belgian drugmaker UCB's, for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy. 22 April 2024
Biosimilars
The European Commission (EC) has granted marketing authorization for Pyzchiva (biosimilar ustekinumab), said Swiss generics and biosimilars company Sandoz. 22 April 2024
Biosimilars
The Icelandic-Israeli pairing of Alvotech and Teva Pharmaceutical Industries have announced that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) injection for subcutaneous use. 17 April 2024
Pharmaceutical
US healthcare giant Johnson & Johnson has announced its financial results for the first quarter of 2024. 16 April 2024
Biotechnology
Swiss inflammatory diseases specialist MoonLake Immunotherapeutics has teamed up with US tech platform company Komodo Health. 10 April 2024
Biotechnology
UCB's Bimzelx (bimekizumab-bkzx) has taken a step closer to a new US approval, with the regulator accepting a supplemental Biologics License Application in hidradenitis suppurativa (HS). 4 April 2024
Biotechnology
US clinical-stage biotech Obsidian Therapeutics has closed a significantly oversubscribed $160.5 million Series C financing. 4 April 2024
Biotechnology
Oruka Therapeutics, a US biotech focused on developing biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, has entered into a merger agreement with ARCA biopharma. 3 April 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze